1 |
Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517.
DOI
|
2 |
Mesquitta, W.T., Wandsnider, M., Kang, H., Thomson, J., Moskvin, O., Suknuntha, K., and Slukvin, I.I. (2019). UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells. Sci. Rep. 9, 6622.
DOI
|
3 |
Mlecnik, B., Bindea, G., Angell, H.K., Sasso, M.S., Obenauf, A.C., Fredriksen, T., Lafontaine, L., Bilocq, A.M., Kirilovsky, A., Tosolini, M., et al. (2014). Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 6, 228ra237.
|
4 |
Naeimi Kararoudi, M., Nagai, Y., Elmas, E., de Souza Fernandes Pereira, M., Ali, S.A., Imus, P.H., Wethington, D., Borrello, I.M., Lee, D.A., and Ghiaur, G. (2020). CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood 136, 2416-2427.
DOI
|
5 |
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 409-412.
DOI
|
6 |
Perica, K., Varela, J.C., Oelke, M., and Schneck, J. (2015). Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med. J. 6, e0004.
DOI
|
7 |
Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013). NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599-3608.
DOI
|
8 |
Romee, R., Cooley, S., Berrien-Elliott, M.M., Westervelt, P., Verneris, M.R., Wagner, J.E., Weisdorf, D.J., Blazar, B.R., Ustun, C., DeFor, T.E., et al. (2018). First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131, 2515-2527.
DOI
|
9 |
Kiessling, R., Klein, E., Pross, H., and Wigzell, H. (1975a). "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol. 5, 117-121.
DOI
|
10 |
Kiessling, R., Klein, E., and Wigzell, H. (1975b). "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112-117.
DOI
|
11 |
Knorr, D.A., Ni, Z., Hermanson, D., Hexum, M.K., Bendzick, L., Cooper, L.J., Lee, D.A., and Kaufman, D.S. (2013). Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl. Med. 2, 274-283.
DOI
|
12 |
Larbi, A., Gombert, J.M., Auvray, C., l'Homme, B., Magniez, A., Feraud, O., Coulombel, L., Chapel, A., Mitjavila-Garcia, M.T., Turhan, A.G., et al. (2012). The HOXB4 homeoprotein promotes the ex vivo enrichment of functional human embryonic stem cell-derived NK cells. PLoS One 7, e39514.
DOI
|
13 |
Lee, D.A. (2019). Cellular therapy: adoptive immunotherapy with expanded natural killer cells. Immunol. Rev. 290, 85-99.
DOI
|
14 |
Liu, E., Marin, D., Banerjee, P., Macapinlac, H.A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020). Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545-553.
DOI
|
15 |
Ueda, T. and Kaneko, S. (2020). Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors. Int. J. Hematol. 2020 Jul 23 [Epub]. https://doi.org/10.1007/s12185-020-02951-5
DOI
|
16 |
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018). Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520-531.
DOI
|
17 |
Mantesso, S., Geerts, D., Spanholtz, J., and Kucerova, L. (2020). Genetic engineering of natural killer cells for enhanced antitumor function. Front. Immunol. 11, 607131.
DOI
|
18 |
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100.
DOI
|
19 |
Sadelain, M., Brentjens, R., and Riviere, I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398.
DOI
|
20 |
Shankar, K., Capitini, C.M., and Saha, K. (2020). Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. Stem Cell Res. Ther. 11, 234.
DOI
|
21 |
Ueda, T., Kumagai, A., Iriguchi, S., Yasui, Y., Miyasaka, T., Nakagoshi, K., Nakane, K., Saito, K., Takahashi, M., Sasaki, A., et al. (2020). Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. Cancer Sci. 111, 1478-1490.
DOI
|
22 |
Umekage, M., Sato, Y., and Takasu, N. (2019). Overview: an iPS cell stock at CiRA. Inflamm. Regen. 39, 17.
DOI
|
23 |
Li, Y., Hermanson, D.L., Moriarity, B.S., and Kaufman, D.S. (2018). Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181-192.e5.
DOI
|
24 |
Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., Yokoyama, W.M., and Ugolini, S. (2011). Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49.
DOI
|
25 |
Wegiel, B., Vuerich, M., Daneshmandi, S., and Seth, P. (2018). Metabolic switch in the tumor microenvironment determines immune responses to anti-cancer therapy. Front. Oncol. 8, 284.
DOI
|
26 |
Shimasaki, N., Jain, A., and Campana, D. (2020). NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200-218.
DOI
|
27 |
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017). Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376, 1038-1046.
DOI
|
28 |
Oei, V.Y.S., Siernicka, M., Graczyk-Jarzynka, A., Hoel, H.J., Yang, W., Palacios, D., Almasbak, H., Bajor, M., Clement, D., Brandt, L., et al. (2018). Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors. Cancer Immunol. Res. 6, 467-480.
DOI
|
29 |
Srpan, K., Ambrose, A., Karampatzakis, A., Saeed, M., Cartwright, A.N.R., Guldevall, K., De Matos, G., Onfelt, B., and Davis, D.M. (2018). Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J. Cell Biol. 217, 3267-3283.
DOI
|
30 |
Yamanaka, S. (2020). Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell 27, 523-531.
DOI
|
31 |
Woll, P.S., Martin, C.H., Miller, J.S., and Kaufman, D.S. (2005). Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J. Immunol. 175, 5095-5103.
DOI
|
32 |
Felices, M., Lenvik, A.J., McElmurry, R., Chu, S., Hinderlie, P., Bendzick, L., Geller, M.A., Tolar, J., Blazar, B.R., and Miller, J.S. (2018). Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 3, e96219.
DOI
|
33 |
Zhu, H., Blum, R.H., Bernareggi, D., Ask, E.H., Wu, Z., Hoel, H.J., Meng, Z., Wu, C., Guan, K.L., Malmberg, K.J., et al. (2020a). Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell 27, 224-237.e6.
DOI
|
34 |
Zhu, H., Blum, R.H., Bjordahl, R., Gaidarova, S., Rogers, P., Lee, T.T., Abujarour, R., Bonello, G.B., Wu, J., Tsai, P.F., et al. (2020b). Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood 135, 399-410.
DOI
|
35 |
Woltjen, K., Oceguera-Yanez, F., Kagawa, H., and Kim, S.I. (2016). At the conflux of human genome engineering and induced pluripotency. In Genome Editing, K. Turksen, ed. (Cham, Switzerland: Springer), pp. 45-64.
|
36 |
Yang, Y. and Lundqvist, A. (2020). Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy. Cancers (Basel) 12, 3586.
DOI
|
37 |
Wrangle, J.M., Velcheti, V., Patel, M.R., Garrett-Mayer, E., Hill, E.G., Ravenel, J.G., Miller, J.S., Farhad, M., Anderton, K., Lindsey, K., et al. (2018). ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 19, 694-704.
DOI
|
38 |
Xu, H., Wang, B., Ono, M., Kagita, A., Fujii, K., Sasakawa, N., Ueda, T., Gee, P., Nishikawa, M., Nomura, M., et al. (2019a). Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566-578.e7.
DOI
|
39 |
Xu, Y., Liu, Q., Zhong, M., Wang, Z., Chen, Z., Zhang, Y., Xing, H., Tian, Z., Tang, K., Liao, X., et al. (2019b). 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J. Hematol. Oncol. 12, 49.
DOI
|
40 |
Yvon, E.S., Burga, R., Powell, A., Cruz, C.R., Fernandes, R., Barese, C., Nguyen, T., Abdel-Baki, M.S., and Bollard, C.M. (2017). Cord blood natural killer cells expressing a dominant negative TGF-beta receptor: implications for adoptive immunotherapy for glioblastoma. Cytotherapy 19, 408-418.
DOI
|
41 |
Zhang, J., Zheng, H., and Diao, Y. (2019). Natural killer cells and current applications of chimeric antigen receptor-modified NK-92 cells in tumor immunotherapy. Int. J. Mol. Sci. 20, 317.
DOI
|
42 |
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J.K., Todani, M., Nakagawa, M., et al. (2019). Induced pluripotent stem cells and their use in human models of disease and development. Physiol. Rev. 99, 79-114.
DOI
|
43 |
Zeng, J., Tang, S.Y., Toh, L.L., and Wang, S. (2017). Generation of "off-the-shelf" natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Reports 9, 1796-1812.
DOI
|
44 |
Myers, J.A. and Miller, J.S. (2021). Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85-100.
DOI
|
45 |
Woll, P.S., Grzywacz, B., Tian, X., Marcus, R.K., Knorr, D.A., Verneris, M.R., and Kaufman, D.S. (2009). Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113, 6094-6101.
DOI
|
46 |
Xie, G., Dong, H., Liang, Y., Ham, J.D., Rizwan, R., and Chen, J. (2020). CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59, 102975.
DOI
|
47 |
Bachanova, V. and Miller, J.S. (2014). NK cells in therapy of cancer. Crit. Rev. Oncog. 19, 133-141.
DOI
|
48 |
Cichocki, F., Bjordahl, R., Gaidarova, S., Mahmood, S., Abujarour, R., Wang, H., Tuininga, K., Felices, M., Davis, Z.B., Bendzick, L., et al. (2020). iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Sci. Transl. Med. 12, eaaz5618.
DOI
|
49 |
Dianat-Moghadam, H., Rokni, M., Marofi, F., Panahi, Y., and Yousefi, M. (2018). Natural killer cell-based immunotherapy: from transplantation toward targeting cancer stem cells. J. Cell. Physiol. 234, 259-273.
DOI
|
50 |
Ferrari de Andrade, L., Tay, R.E., Pan, D., Luoma, A.M., Ito, Y., Badrinath, S., Tsoucas, D., Franz, B., May, K.F., Jr., Harvey, C.J., et al. (2018). Antibodymediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science 359, 1537-1542.
DOI
|
51 |
Delconte, R.B., Kolesnik, T.B., Dagley, L.F., Rautela, J., Shi, W., Putz, E.M., Stannard, K., Zhang, J.G., Teh, C., Firth, M., et al. (2016). CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17, 816-824.
DOI
|
52 |
Gornalusse, G.G., Hirata, R.K., Funk, S.E., Riolobos, L., Lopes, V.S., Manske, G., Prunkard, D., Colunga, A.G., Hanafi, L.A., Clegg, D.O., et al. (2017). HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat. Biotechnol. 35, 765-772.
DOI
|
53 |
Imai, C., Iwamoto, S., and Campana, D. (2005). Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376-383.
|